| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11904-016-0329-5 |
| P698 | PubMed publication ID | 27485838 |
| P2093 | author name string | Keyur Patel | |
| Tzu-Hao Lee | |||
| Bassem Matta | |||
| P2860 | cites work | Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C | Q24563264 |
| Chronic hepatitis C and liver fibrosis. | Q26825671 | ||
| Hepatitis C in the HIV-Infected Person | Q28206126 | ||
| Clinical practice. Chronic hepatitis C infection | Q28241445 | ||
| Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade | Q28547529 | ||
| Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. | Q31090448 | ||
| Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients | Q33502234 | ||
| A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI) | Q33877980 | ||
| Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus | Q34044333 | ||
| Risk factors for fatty liver in the Multicenter AIDS Cohort Study | Q34049896 | ||
| Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: A comparative study | Q34200861 | ||
| Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 | ||
| Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection | Q34438649 | ||
| Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. | Q34630054 | ||
| Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02. | Q34757375 | ||
| Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease | Q34812618 | ||
| Hepatotoxicity of antiretroviral therapy | Q35182704 | ||
| Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy | Q35588143 | ||
| Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes | Q35760270 | ||
| Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. | Q51830742 | ||
| Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. | Q51836061 | ||
| A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. | Q54059121 | ||
| Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? | Q54397608 | ||
| Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis | Q56980632 | ||
| EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis | Q57782665 | ||
| EASL Recommendations on Treatment of Hepatitis C 2015 | Q58324800 | ||
| Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis | Q61763027 | ||
| Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients | Q73036086 | ||
| Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients | Q80256441 | ||
| Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease | Q82648058 | ||
| Liver biopsy | Q83395480 | ||
| Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study | Q83482709 | ||
| Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis | Q83978119 | ||
| Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results | Q84609172 | ||
| Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study | Q84814912 | ||
| Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease | Q87406034 | ||
| Elevated liver enzymes following initiation of antiretroviral therapy | Q93934275 | ||
| Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy | Q35791614 | ||
| Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. | Q36718901 | ||
| Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review | Q36912964 | ||
| Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis | Q37265953 | ||
| Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. | Q37275793 | ||
| Nonalcoholic fatty liver disease among HIV-infected persons | Q37434578 | ||
| Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs | Q37619741 | ||
| Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis | Q37841383 | ||
| Noninvasive methods to assess liver disease in patients with hepatitis B or C. | Q38005794 | ||
| The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease | Q38212222 | ||
| Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis | Q38259431 | ||
| Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. | Q38602682 | ||
| Biochemical non-invasive assessment of liver fibrosis cannot replace biopsy in HIV-HCV coinfected patients | Q40253122 | ||
| Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells | Q40936119 | ||
| The role of laparoscopy in the diagnosis of cirrhosis | Q41090967 | ||
| Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs | Q41632410 | ||
| Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration | Q42272013 | ||
| Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. | Q42923153 | ||
| Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection | Q42983442 | ||
| Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. | Q42990078 | ||
| Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection | Q43056741 | ||
| Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice | Q43151611 | ||
| Description of liver disease in a cohort of HIV/HBV coinfected patients. | Q43246288 | ||
| Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers | Q43615259 | ||
| Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model | Q44151781 | ||
| Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients | Q44235407 | ||
| Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort | Q44381562 | ||
| The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values | Q44513485 | ||
| Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. | Q44707599 | ||
| Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection | Q44920531 | ||
| HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). | Q44933768 | ||
| Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival | Q45334756 | ||
| Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease | Q45346653 | ||
| Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). | Q45369097 | ||
| Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis. | Q45383974 | ||
| Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy | Q45387923 | ||
| Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. | Q45392148 | ||
| The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. | Q45400018 | ||
| Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients | Q45421063 | ||
| Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients | Q45728692 | ||
| Insulin resistance in HIV infection: drugs, host responses, or restoration to health? | Q46005324 | ||
| Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index | Q46490993 | ||
| Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors | Q46557460 | ||
| A novel panel of blood markers to assess the degree of liver fibrosis | Q46827711 | ||
| Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). | Q46857868 | ||
| Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. | Q51444679 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 279-288 | |
| P577 | publication date | 2016-08-02 | |
| P1433 | published in | Current HIV/AIDS reports | Q26842190 |
| P1476 | title | Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. | |
| P478 | volume | 13 |
| Q47553589 | Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy |
| Q89887683 | Impact of HIV and chronic kidney disease comorbidities on hepatitis C treatment choices, drug-drug interactions and hepatitis C cure |
| Q39238714 | Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. |
| Q48097218 | Peripheral TNFα elevations in abstinent alcoholics are associated with hepatitis C infection |
| Q38753617 | Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. |
Search more.